Wang YJ, Chan YN, Jheng YW, et al. - In breast cancer survivors being treated with taxane, researchers conducted this prospective, longitudinal study to prospectively examine the severity and prevalence of chemotherapy-induced peripheral neuropathy (CIPN) and to explore the association between clinician-assessed (objective) and patient-reported (subjective) CIPN. In order to recruit women newly diagnosed with breast cancer and about to receive taxane, purposive sampling was adapted. There were 88 participants involved in this study. The change of CIPN prevalence and severity in survivors newly diagnosed with breast cancer were significant over time. Particularly, the severest and highest CIPN was observed at the end of chemotherapy. Even 3 months after the end of chemotherapy, survivors were still suffering from CIPN. Mild to moderate associations between clinician-assessed and patient-reported CIPN were identified.